Hoe Venetia, Yao Henry H, Gough Karla, O'Connell Helen E
Department of Urology Western Health Footscray Victoria Australia.
Department of Surgery The University of Melbourne Melbourne Victoria Australia.
BJUI Compass. 2023 Jan 25;4(3):269-276. doi: 10.1002/bco2.218. eCollection 2023 May.
Knowledge of factors associated with superior outcomes in women treated with urethral bulking agents for stress urinary incontinence (SUI) remains limited. The aim of this study was to examine associations between post-treatment outcomes in women who had undergone polyacrylamide hydrogel injections for SUI, and physiological and self-reported variables captured during pre-treatment clinical evaluation. A cross-sectional study was undertaken in female patients treated for SUI with polyacrylamide hydrogel injections by a single urologist between January 2012 and December 2019. Post-treatment outcome data were gathered in July 2020 using the Patient Global Impression of Improvement (PGI-I), Urinary Distress Inventory-short form (UDI-6), Incontinence Impact Questionnaire (IIQ7), and International Consultation on Incontinence Questionnaire Short Form (ICIQ SF). All other data were gathered from women's medical records including pre-treatment patient-reported outcomes. Associations between post-treatment outcomes and pre-treatment physiological and self-reported variables were investigated using regression models. One hundred seven of the 123 eligible patients completed post-treatment patient-reported outcome measures. Mean age was 63.1 years (range 25-93 years), and median time between first injection and follow-up was 51 months (inter-quartile range 23.5-70 months). Fifty-five (51%) women had a successful outcome based on PGI-I scores. Women with type 3 urethral hypermobility pre-treatment were more likely to report treatment success (PGI-I). Poor bladder compliance pre-treatment was associated with greater urinary distress, frequency and severity (UDI-6 and ICIQ) post-treatment. Older age was associated with worse urinary frequency and severity (ICIQ) post-treatment. Associations between patient-reported outcomes and time between first injection and follow-up were trivial and not statistically significant. Severity of pre-treatment incontinence impact (IIQ-7) was associated with worse incontinence impact post-treatment. Type 3 urethral hypermobility was associated with a successful outcome, whereas pre-treatment incontinence impact, poor bladder compliance and older age were associated with poorer self-reported outcomes. Long-term efficacy appears to hold in those who responded to initial treatment.
对于接受尿道填充剂治疗压力性尿失禁(SUI)的女性,与更好治疗结果相关的因素的了解仍然有限。本研究的目的是检查接受聚丙烯酰胺水凝胶注射治疗SUI的女性的治疗后结果与治疗前临床评估期间记录的生理和自我报告变量之间的关联。对2012年1月至2019年12月期间由一名泌尿科医生用聚丙烯酰胺水凝胶注射治疗SUI的女性患者进行了一项横断面研究。2020年7月使用患者整体改善印象(PGI-I)、排尿困扰问卷简表(UDI-6)、尿失禁影响问卷(IIQ7)和国际尿失禁咨询问卷简表(ICIQ SF)收集治疗后结果数据。所有其他数据均从女性病历中收集,包括治疗前患者报告的结果。使用回归模型研究治疗后结果与治疗前生理和自我报告变量之间的关联。123名符合条件的患者中有107名完成了治疗后患者报告的结果测量。平均年龄为63.1岁(范围25 - 93岁),首次注射与随访之间的中位时间为51个月(四分位间距23.5 - 70个月)。根据PGI-I评分,55名(51%)女性治疗成功。治疗前3型尿道活动过度的女性更有可能报告治疗成功(PGI-I)。治疗前膀胱顺应性差与治疗后更大的排尿困扰、频率和严重程度(UDI-6和ICIQ)相关。年龄较大与治疗后更差的尿频和严重程度(ICIQ)相关。患者报告的结果与首次注射和随访之间的时间之间的关联微不足道且无统计学意义。治疗前尿失禁影响的严重程度(IIQ-7)与治疗后更差的尿失禁影响相关。3型尿道活动过度与成功结果相关,而治疗前尿失禁影响、膀胱顺应性差和年龄较大与较差的自我报告结果相关。长期疗效似乎在那些对初始治疗有反应的患者中持续存在。